News Releases

Date Title
01/17/19
Summary ToggleSunesis Announces Pricing of $20 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock
01/17/19
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock and Preferred Stock SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public
01/02/19
Summary ToggleSunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies - 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent